![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Retrospective Comparison of Etravirine and Darunavir/Ritonavir as Dual Therapy in Early Treatment-Experienced Subjects (INROADS) to a Matched Historical Control Cohort
|
|
|
INROADS was a Phase 2b, single-arm, open-label, multicenter, 48-week US trial that evaluated ETR 400mg (two 200mg tablets) and DRV/r 800/100mg (two 400mg tablets DRV, 1 tablet ritonavir), all qd, in HIV-1-infected, ARV treatment-experienced adults sensitive to DRV and ETR, or in treatment-naïve adults who were infected with a strain of HIV-1 already resistant to 1 or more drugs (transmitted resistance)
"Overall efficacy (HIV-1 RNA <50 copies/mL) was 87% (32/37) (CVR, non-VF censored at Week 48; primary end point).......Black subjects in INROADS achieved CVR (<50 HIV-1 RNA copies/mL) at Week 48 (96%, 21/22)"
Reported by Jules Levin
14th European AIDS Conference (EACS), Brussels, Belgium, October 16-19, 2013.
Peter Ruane,1 Javier Morales-Ramirez,2 Harold Katner,3 Chiu-Bin Hsiao,4 Bruce Coate,5 Robert Ryan,5 Michelle Cho,6 David Anderson6
1Peter J. Ruane MD Inc, Los Angeles, California, USA; 2Clinical Research Puerto Rico Inc., San Juan, Puerto Rico; 3Mercer University School of Medicine, Department of Internal Medicine, Macon, Georgia, USA; 4The Positive Health Clinic, Allegheny General Hospital,
Pittsburgh, Pennsylvania, USA; 5Janssen Research & Development, Titusville, New Jersey, USA; 6Janssen Services, LLC, Titusville, New Jersey, USA
![EACS1.gif](../images/102113/102113-4/EACS1.gif)
![EACS2.gif](../images/102113/102113-4/EACS2.gif)
![EACS3.gif](../images/102113/102113-4/EACS3.gif)
![EACS4.gif](../images/102113/102113-4/EACS4.gif)
![EACS5.gif](../images/102113/102113-4/EACS5.gif)
![EACS6.gif](../images/102113/102113-4/EACS6.gif)
![EACS7.gif](../images/102113/102113-4/EACS7.gif)
![EACS8.gif](../images/102113/102113-4/EACS8.gif)
![EACS9.gif](../images/102113/102113-4/EACS9.gif)
![EACS10.gif](../images/102113/102113-4/EACS10.gif)
![EACS11.gif](../images/102113/102113-4/EACS11.gif)
![EACS12.gif](../images/102113/102113-4/EACS12.gif)
![EACS13.gif](../images/102113/102113-4/EACS13.gif)
![EACS14.gif](../images/102113/102113-4/EACS14.gif)
![EACS15.gif](../images/102113/102113-4/EACS15.gif)
![EACS16.gif](../images/102113/102113-4/EACS16.gif)
![EACS17.gif](../images/102113/102113-4/EACS17.gif)
![EACS18.gif](../images/102113/102113-4/EACS18.gif)
![EACS19.gif](../images/102113/102113-4/EACS19.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|